FDA approves Sun Pharma’s JAK inhibitor for alopecia
The FDA approval is based on data gathered from two Phase III studies where over 30% of the patients gained 80% or more coverage of scalp hair.
The FDA approval is based on data gathered from two Phase III studies where over 30% of the patients gained 80% or more coverage of scalp hair.
What's Your Reaction?
